BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25322341)

  • 1. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection.
    Pysz MA; Machtaler SB; Seeley ES; Lee JJ; Brentnall TA; Rosenberg J; Tranquart F; Willmann JK
    Radiology; 2015 Mar; 274(3):790-9. PubMed ID: 25322341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging.
    Deshpande N; Ren Y; Foygel K; Rosenberg J; Willmann JK
    Radiology; 2011 Mar; 258(3):804-11. PubMed ID: 21339349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the Clinical Development and Validation of a Thy1-Targeted Ultrasound Contrast Agent for the Early Detection of Pancreatic Ductal Adenocarcinoma.
    Bam R; Daryaei I; Abou-Elkacem L; Vilches-Moure JG; Meuillet EJ; Lutz A; Marinelli ER; Unger EC; Gambhir SS; Paulmurugan R
    Invest Radiol; 2020 Nov; 55(11):711-721. PubMed ID: 32569010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
    Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
    Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model.
    Shimamoto N; Ito M; Chiba M; Honma S; Imazu H; Sumiyama K
    Hepatobiliary Pancreat Dis Int; 2020 Oct; 19(5):478-485. PubMed ID: 32265136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
    Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
    Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
    Willmann JK; Lutz AM; Paulmurugan R; Patel MR; Chu P; Rosenberg J; Gambhir SS
    Radiology; 2008 Sep; 248(3):936-44. PubMed ID: 18710985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
    Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
    Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent.
    Abou-Elkacem L; Wilson KE; Johnson SM; Chowdhury SM; Bachawal S; Hackel BJ; Tian L; Willmann JK
    Theranostics; 2016; 6(11):1740-52. PubMed ID: 27570547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice.
    Willmann JK; Cheng Z; Davis C; Lutz AM; Schipper ML; Nielsen CH; Gambhir SS
    Radiology; 2008 Oct; 249(1):212-9. PubMed ID: 18695212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1.
    Foygel K; Wang H; Machtaler S; Lutz AM; Chen R; Pysz M; Lowe AW; Tian L; Carrigan T; Brentnall TA; Willmann JK
    Gastroenterology; 2013 Oct; 145(4):885-894.e3. PubMed ID: 23791701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
    Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC
    J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
    Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
    Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study.
    Nishida M; Koito K; Hirokawa N; Hori M; Satoh T; Hareyama M
    Ultrasound Med Biol; 2009 Feb; 35(2):175-85. PubMed ID: 18845377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
    Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
    Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55).
    Bzyl J; Palmowski M; Rix A; Arns S; Hyvelin JM; Pochon S; Ehling J; Schrading S; Kiessling F; Lederle W
    Eur Radiol; 2013 Feb; 23(2):468-75. PubMed ID: 22878592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment.
    Grouls C; Hatting M; Rix A; Pochon S; Lederle W; Tardy I; Kuhl CK; Trautwein C; Kiessling F; Palmowski M
    Radiology; 2013 May; 267(2):487-95. PubMed ID: 23360735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thy1-Targeted Microbubbles for Ultrasound Molecular Imaging of Pancreatic Ductal Adenocarcinoma.
    Abou-Elkacem L; Wang H; Chowdhury SM; Kimura RH; Bachawal SV; Gambhir SS; Tian L; Willmann JK
    Clin Cancer Res; 2018 Apr; 24(7):1574-1585. PubMed ID: 29301827
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).
    Pysz MA; Foygel K; Rosenberg J; Gambhir SS; Schneider M; Willmann JK
    Radiology; 2010 Aug; 256(2):519-27. PubMed ID: 20515975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative perfusion analysis of transabdominal contrast-enhanced ultrasonography of pancreatic masses and carcinomas.
    Kersting S; Konopke R; Kersting F; Volk A; Distler M; Bergert H; Saeger HD; Grützmann R; Bunk A
    Gastroenterology; 2009 Dec; 137(6):1903-11. PubMed ID: 19715694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.